Core Viewpoint - BeiGene's stock experienced a slight decline of 0.73% on March 31, with a trading volume of 738 million yuan, indicating a low financing balance relative to its market value [1] Financing Summary - On March 31, BeiGene had a financing buy amount of 63.91 million yuan and a financing repayment of 50.01 million yuan, resulting in a net financing purchase of 13.91 million yuan [1] - The total financing and securities balance for BeiGene reached 855 million yuan, with the financing balance at 836 million yuan, accounting for 3.11% of the circulating market value, which is below the 30th percentile level over the past year [1] Securities Lending Summary - On March 31, BeiGene repaid 4,026 shares in securities lending and sold 2,838 shares, with the selling amount calculated at 662,900 yuan [1] - The remaining securities lending volume was 79,400 shares, with a balance of 18.56 million yuan, exceeding the 90th percentile level over the past year, indicating a high level [1] Company Overview - BeiGene, established on October 28, 2010, and listed on December 15, 2021, is located in Changping District, Beijing, and focuses on the research, development, production, and commercialization of innovative drugs [1] - The company's main revenue sources are 99.10% from drug sales and 0.90% from collaboration arrangements [1] Shareholder Information - As of September 30, 2025, BeiGene had 36,200 shareholders, an increase of 55.33% from the previous period, while the average circulating shares per person decreased by 35.79% to 3,195 shares [2] - For the period from January to September 2025, BeiGene reported a revenue of 27.595 billion yuan, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion yuan, up 130.88% year-on-year [2] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [2]

Core Insights - The Chinese innovative pharmaceutical industry has shown remarkable growth in Q1 2026, with a total of over $60 billion in out-licensing (BD) transactions, nearing half of the projected total for 2025 of $135.7 billion [1] - The increasing interest from multinational corporations (MNCs) and overseas private equity (PE) firms in Chinese assets indicates a rising international recognition and quality of Chinese innovative drugs [1][2] - The trend of BD transactions has shifted from being sporadic to a systematic approach, with Chinese projects accounting for over 70% of significant global deals [5] Group 1: Market Dynamics - In Q1 2026, significant BD transactions included China National Pharmaceutical Group's $1.53 billion deal with Sanofi and Eucure Biopharma's $1.18 billion deal with UCB [4] - The number of Chinese innovative drug BD projects and disclosed amounts accounted for 20% and 75% of the global totals, respectively [5] - The most active sectors for BD transactions include bispecific antibodies, ADCs, and GLP-1 receptor agonists, with substantial growth in upfront payments [5][10] Group 2: Financial Implications - BD revenues are transforming the financial structures of innovative pharmaceutical companies, allowing them to secure significant upfront and milestone payments during the R&D phase [6] - For instance, 2025 projections indicate that Chinese pharmaceutical companies will have 165 BD projects, with upfront payments exceeding $7.03 billion, marking a 226.8% increase [6] - Companies like Sanofi and Innovent Biologics are expected to see substantial revenue growth due to strategic partnerships, with projected revenues for 2025 reaching approximately $4.2 billion and $2.9 billion, respectively [6] Group 3: Evolving Collaboration Models - The NewCo model is gaining traction, allowing companies to establish overseas entities for specific pipeline rights while retaining original rights for long-term benefits [9] - This model balances traditional licensing with self-commercialization, exemplified by companies like Hengrui Medicine [9] - The collaboration between Innovent Biologics and Eli Lilly illustrates a mature partnership model, moving beyond simple licensing to long-term strategic cooperation [9] Group 4: Future Outlook - The Chinese innovative drug sector is poised for continued growth, with expectations of over 10 new drug approvals and a projected revenue increase of over 25% in 2026 [15] - The government is emphasizing high-quality development in innovative drugs and medical devices, further supporting the industry's growth [15] - The ongoing clinical development and increasing number of IND applications indicate a stable upward trend in the innovative drug market [14][15]

Investment Rating - The report indicates a positive outlook on the Chinese innovative drug industry chain, with a focus on business development (BD), policy, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, reflecting accelerated global cooperation value [2][11]. - The Chinese government has upgraded its strategic positioning of the biopharmaceutical industry, marking it as a "new emerging pillar industry" in the 2026 government work report [2][15]. - Clinical activity is on the rise, with Chinese innovative drug R&D entering a high-quality harvest period, as evidenced by a significant increase in the number of innovative drugs entering clinical trials and being approved for market [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector rose by 1.56% this week, ranking 4th out of 31 sectors, while it has seen a year-to-date decline of 1.38%, ranking 17th [1][10]. Industry Dynamics - In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions, and the first quarter of 2026 has already seen over $60 billion in transactions [2][11]. - The first version of the commercial health insurance innovative drug catalog was officially launched, enhancing the multi-layered payment system for innovative drugs [2][15]. - By the end of 2025, China accounted for 33.7% of the global innovative drugs in development, leading the world, with 827 innovative drugs entering clinical trials for the first time [2][16][19]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value of up to $2.75 billion, validating the commercial potential of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Achieved revenue of 3.056 billion yuan in 2025, a year-on-year increase of 43.9%, driven by core dual-antibody products [3][24]. - **Innovent Biologics**: Reported total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first year of profitability with a significant growth in product revenue [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, with a focus on the commercialization of its core ADC products [3][26]. - **Ascletis Pharma**: Achieved record revenue of 7.731 billion yuan in 2025, with innovative drugs accounting for 81.5% of total revenue [3][27]. - **Zai Lab**: Reported revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative pharmaceuticals, particularly in the context of China's biopharmaceutical sector and its international expansion - **Market Growth**: The total value of BD (Business Development) transactions for innovative drugs is projected to reach $137.7 billion by 2025, a 1.6 times increase year-on-year, significantly surpassing the electric vehicle sector's $74 billion in the same timeframe [1][2][3] Core Insights and Arguments - **International Expansion**: The innovative drug sector is experiencing explosive growth in international markets, with Q1 2026 BD transactions already reaching $60 billion, accounting for 46% of the total for 2025 [1][2] - **Policy Support**: Biopharmaceuticals have been designated as a new pillar industry by the Chinese government, shifting focus from public welfare to GDP contribution, indicating a supportive policy environment for growth [2][3] - **Performance Expectations**: Companies like Heng Rui Medicine are expected to see over 30% growth in innovative drug revenue by 2026, with significant contributions from key products [1][3] - **Clinical Developments**: Major clinical data releases are anticipated from key conferences such as AACR and ASCO, which could catalyze market movements [1][5] Notable Companies and Their Prospects - **Heng Rui Medicine**: Expected to achieve over 30% growth in innovative drug revenue, with a strong pipeline of 53 products anticipated for approval between 2022 and 2028 [15] - **Kangfang Biopharma**: Key product AK112 is set to release critical clinical data in 2026, which could significantly impact its market position [11][13] - **Baiyi Shenzhou**: Projected profits of $700-800 million in 2026, indicating a rapid profit climb [1][8] - **Xinda Biopharma**: Anticipated to benefit from new product approvals and commercial launches, with a focus on expanding its product pipeline [6][8] Investment Opportunities - **Recommended Stocks**: Key investment targets include Kangfang Biopharma, Xinda Biopharma, Baiyi Shenzhou, and Kelong Biotechnology in the H-share market, and Xintai, Haishike, and Heng Rui Medicine in the A-share market [4][8] - **Undervalued Stocks**: Companies like Hot Scene Biopharma and Yifang Biopharma, which have seen significant price declines, are suggested for bottom-fishing opportunities [4][8] Emerging Trends - **Small RNA Technology**: The small RNA sector is entering a critical phase with breakthroughs in liver-targeted delivery technologies, and several companies are expected to announce significant clinical data in 2026 [18][22] - **Clinical Data Impact**: Recent clinical data from companies like Serapta and Wave Life Sciences highlight the potential and challenges within the small RNA space, influencing market sentiment and investment strategies [20][21] Conclusion - The innovative pharmaceutical sector in China is poised for significant growth driven by international expansion, supportive policies, and strong company performances. Key clinical events and emerging technologies present substantial investment opportunities, particularly in small RNA and innovative drug development.

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 30, 2026 [3]. Core Insights - The innovative drug sector is experiencing a significant configuration moment, with major domestic pharmaceutical companies reporting rapid growth in innovative drugs. The development model has shifted from solely relying on financing to a comprehensive approach that includes product commercialization, overseas R&D licensing, and financing [4]. - The Chinese innovative drug market is witnessing a surge in outbound business development (BD) events, with 49 BD events recorded by March 25, 2026, totaling over $33 billion in upfront payments and nearly $57 billion in total deal value [4]. - The innovative drug index outperformed the CSI 300 index by 4.44 percentage points during the week of March 21-27, 2026, with a growth rate of 3.03% [4]. Summary by Sections 1. Innovative Drug Highlights - Major companies like Heng Rui Medicine and China Biopharmaceutical have reported rapid growth in innovative drugs, with biotech firms like BeiGene and Innovent Biologics turning significant losses into profits [4]. - The trend of Chinese innovative drugs going global is strong, with a notable increase in BD events and deal values compared to previous years [4]. 2. Tumor Immunotherapy 2.0 Era - China continues to lead in the development of PD-1/VEGF bispecific antibodies, with significant partnerships and clinical advancements [5]. - The market potential for PD-1 bispecific antibodies is expected to surpass that of single-agent PD-1 therapies, with ongoing collaborations and clinical trials [5]. 3. New Technologies and Molecules - The ADC (Antibody-Drug Conjugate) sector is seeing innovations with new payloads and combinations, with Chinese companies making significant strides in this area [6]. - The introduction of new technologies, such as tumor microenvironment-activated drugs, is expected to expand the applicability of ADCs [6]. 4. Small RNA Collaborations - The small RNA sector is experiencing accelerated collaboration and acquisitions, with significant deals and partnerships being established in 2026 [7]. - The market for small RNA drugs is rapidly industrializing, with notable sales growth for products like Leqvio, which achieved $1.2 billion in sales in the 2025 fiscal year [7]. 5. Price Leadership in Raw Materials - The report highlights the price increases in vitamins and raw materials due to geopolitical tensions and supply chain dynamics, with specific products like Vitamin E and A seeing significant price hikes [9]. - The report notes that certain raw materials have maintained price leadership, allowing for rapid price increases in specific categories [9]. 6. Cost Pass-Through in Gloves - The report discusses the cost increases in nitrile and PVC gloves due to rising raw material prices, with significant price elasticity observed in these products [10]. - The report indicates that the supply chain dynamics are shifting, providing competitive advantages for Chinese manufacturers in the global market [10]. 7. Two-Way Item Management - The management of dual-use items is expected to create pricing advantages for domestic medical products, leveraging China's unique resource endowments [11]. - The report suggests that stricter controls on key materials could enhance the competitive position of Chinese medical products in international markets [11]. 8. Stock Recommendations - The report recommends several companies based on their positioning in innovative drugs, ADCs, small RNA, and raw materials, including Rongchang Biopharmaceutical, Sunway Biopharma, and others [12][13].

Core Viewpoint - The application for BGB-43395 tablets by BeiGene (Suzhou) Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration on March 28, 2026, with acceptance number CXHB2600089 [1][3]. Company Information - BeiGene (Suzhou) Biotechnology Co., Ltd. was established on April 9, 2015, and is a large-scale limited liability company wholly owned by Hong Kong and Macao investors [3][6]. - The legal representative of the company is Xiaobin Wu, and it operates in the field of medical research and experimental development [3][6]. - The company has a registered capital of approximately 4.973 billion RMB and a paid-in capital of approximately 3.444 billion RMB [3][6]. - The company is located in the Suzhou Industrial Park, Jiangsu Free Trade Zone, at Jin Hai Road No. 29 [3][6]. Application Details - The drug BGB-43395 is classified as a chemical drug and the application type is a supplementary application [2][4]. - The registration classification for the drug is categorized as type 1 [2][4].

Core Viewpoint - The innovative drug sector is experiencing significant growth, with multiple companies seeing substantial stock price increases, indicating a bullish trend in the market [1]. Group 1: Stock Performance - Shuyatain's stock price increased by 14.66%, reaching 26.52 [2] - Other notable performers include Dizhe Pharmaceutical with a 10.70% increase, Baili Tianheng at 10.63%, and Huana Pharmaceutical at 10.33% [2] - In the Hong Kong market, Keystone Pharmaceuticals surged over 18%, while CSPC Pharmaceutical and Xiansheng Pharmaceutical rose by over 12% and 8%, respectively [3] Group 2: Market Trends - The overall trend in the innovative drug sector shows a strong upward movement, with several companies hitting their daily price limits [1] - The performance of stocks in both mainland and Hong Kong markets reflects a growing investor confidence in the pharmaceutical industry [3]

Core Insights - The company achieved a total revenue of $5.343 billion in 2025, marking a year-on-year growth of 40.2%, with product revenue netting $5.282 billion, up 39.8% [1][3] - The company recorded a net profit of $287 million in 2025, a significant turnaround from a net loss of $645 million in the previous year, indicating a sustainable growth phase for its business model [1][3] Revenue Breakdown - The core product, Baiyueze, generated global sales of $3.928 billion, reflecting a 48.6% increase and maintaining its leading position among BTK inhibitors [1][3] - Baiyueze accounted for approximately 74% of total product revenue, while Baizean (Tislelizumab) contributed $737 million, up 18.8% [3] - Other products included Anjavi (Denosumab) with $306 million in revenue, up 36.4%, and Beilitai (Bonetuzumab) with $104 million, up 40.2% [3] Cash Flow and Profitability - Cash and cash equivalents reached $4.548 billion by the end of 2025, a 73.1% increase, with net cash flow from operating activities at $1.128 billion, a turnaround from a net outflow of $141 million in the previous year [1][3] - The gross profit for 2025 was $4.667 billion, with a gross margin of 87.3%, an improvement from 84.3% in 2024 [4] Cost Management - The increase in gross margin was attributed to a higher proportion of high-margin Baiyueze sales, ongoing optimization of manufacturing costs, and the gradual operationalization of the Hopewell production facility [4] - Research and development expenses rose to $2.146 billion, a 9.9% increase, while sales and administrative expenses reached $2.081 billion, up 13.7% [5][7] Financial Health - As of the end of 2025, total assets amounted to $8.189 billion, with shareholder equity at $4.361 billion and total liabilities at $3.827 billion [7] - The company secured a credit agreement with HSBC and other financial institutions for approximately $768 million to refinance short-term operational funding [7] Pipeline Progress - The company is advancing its pipeline with the approval of Sotoclis (a next-generation BCL2 inhibitor) for treating relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia, with FDA priority review status [8] - The HERIZON-GEA-01 study for Baihe'an (Zanidatamab) achieved positive endpoints, paving the way for a market application for HER2-positive gastric esophageal adenocarcinoma [8]

Group 1 - The company announced the appointment of Ernst & Young Huaming as the annual audit institution for its A-share financial statements and internal controls [1] - Ernst & Young will serve as the annual audit institution for the company's Hong Kong stock financial statements [1] - Ernst & Young LLP has been appointed as the annual audit institution for the company's U.S. stock financial statements and internal controls [1] - Ernst & Young AG will act as the statutory auditor for the company in Switzerland [1]